Browse drugs

…t related adverse events was 66.7% (269 of 403 patients) in the carboplatin arm and 55.0% (222 of 404 patients) in the control arm. No trea…

…ypically delivered 5 days a week over 7 weeks concurrently with cisplatin, a regimen established through multiple randomised trials, demo…

…64.4%) AT and 25 (55.6%) HP.The AT most frequently involved was paclitaxel (50; 11.3%), followed by cyclophosphamide (37; 8.4%), doxorubic…

… consistent with the known toxicity profiles of carboplatin and gemcitabine. Notably, grade ≥3 AEs were predominantly hematological, with m…

…red, followed by either 10 mg/kg of bevacizumab or 2.4 mg/kg of carboplatin. Serial MRI was obtained post-treatment to assess tumor respons…

…as ‘related,’ ‘most possibly related,’ or ‘possibly related’ to SSGJ-707 or tislelizumab.Abstract 1328 Figure 1Waterfall plots for SSGJ-…

…nd using adjusted ideal weight (AIW) in these patients to avoid carboplatin overdose and associated toxicity.Aim and Objectives Retrospecti…

…in response to both single-agent and combination treatment with carboplatin and docetaxel. Multiparameter flow cytometry demonstrated a het…

…minantly stereotactic radiosurgery (SRS)) followed by continued osimertinib, with encouraging PFS/OS and acceptable toxicity. By contrast, …

…tatic lung adenocarcinoma receiving carboplatin, pemetrexed and pembrolizumab presented with subacute bilateral lower limb oedema and erythem…

…ents and those treated with standard neoadjuvant HER2 therapies paclitaxel, with or without carboplatin, trastuzumab and pertuzumab (Taxol…

…9 life years; 95% CI 7929 to 8220; 10.8%; figure 4). The use of nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…